Illumina (XTER:ILU) ROCE %: 14.50% (As of Mar. 2026)


XTER:ILU Illumina Inc XTER:ILU
76 GF Score
Price €124.28
GF Value €90.37
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Illumina ROCE %?

Illumina XTER:ILU +0.60% 76 ROCE % is 14.50% as of Mar. 2026. GuruFocus rates XTER:ILU with a GF Score™ of 76/100 and a GF Value™ of €90.37 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Illumina's annualized ROCE % for the quarter that ended in Mar. 2026 was 14.50%.

Illumina  (XTER:ILU) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Illumina ROCE % Related Terms

Illumina ROCE % Historical Data

* Premium members only.

The historical data trend for Illumina's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina ROCE % Chart

Illumina Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.44 -37.94 -11.37 -16.65 22.88

Illumina Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.16 27.34 21.97 34.80 14.50
XTER:ILU
76GF Score
Illumina Inc XTER:ILU
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Illumina ROCE % Calculation

Illumina's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=1013.698/( ( (6019.365 - 1477.385) + (5673.976 - 1353.59) )/ 2 )
=1013.698/( (4541.98+4320.386)/ 2 )
=1013.698/4431.183
=22.88 %

Illumina's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=626.26/( ( (5673.976 - 1353.59) + (5673.535 - 1354.59) )/ 2 )
=626.26/( ( 4320.386 + 4318.945 )/ 2 )
=626.26/4319.6655
=14.50 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 14.50% mean?
Illumina (XTER:ILU) has a ROCE % of 14.50% as of Mar. 2026.
Is Illumina's ROCE % too high?
Illumina's current ROCE % is 14.50%. Overall, Illumina has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Illumina's ROCE % compare to MTD and DGX?
Illumina's ROCE % of 14.50% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Illumina's current ROCE % is 14.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Based on GuruFocus' analysis, Illumina (XTER:ILU) is currently considered Significantly Overvalued. The stock's GF Value™ is €90.37, compared to a current price of €124.28 — trading 37.5% above its estimated fair value. The current ROCE % is 14.50%. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Illumina (XTER:ILU), the current ROCE % is 14.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Illumina (XTER:ILU) Overvalued in 2026?

Based on GuruFocus' analysis, Illumina stock appears to be overvalued. The current stock price of €124.28 is trading 37.5% above its estimated GF Value™ of €90.37. GuruFocus considers Illumina to be Significantly Overvalued.

Key valuation signals for XTER:ILU:

  • ROCE %: 14.50%
  • GF Value™: €90.37 vs. price of €124.28 (37.5% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XTER:ILU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Illumina Business Description

Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score

Get the complete analysis for XTER:ILU

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€124.28
Price
€90.37
GF Value